deleobuvir: Clinical Trials

3 trials of deleobuvir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 withdrawn. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Completed 2, Withdrawn 1

Follow deleobuvir: new trials by email Literature Review of deleobuvir trials Research Report on deleobuvir

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients
BI 201335, ribavirin, BI 207127 - Hepatitis C, Chronic
Phase 3WithdrawnBoehringer Ingelheim2013-05-012014-01-23
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Ribavirin (RBV), BI 201335 (Faldaprevir), BI 207127 - Hepatitis C, Chronic
Phase 3CompletedBoehringer Ingelheim4702012-12-012016-04-18
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
BI 207127-placebo: 8-week treatment, Ribavirin: 24-week treatment, BI 207127: 24-week treatment - Hepatitis C, Chronic
Phase 3CompletedBoehringer Ingelheim4962012-11-012016-02-12

Conditions studied

Hepatitis C, Chronic (3)

Sponsors

Boehringer Ingelheim (3)

Countries

Spain (3)  ·  Australia (2)  ·  Canada (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Portugal (2)  ·  United Kingdom (2)  ·  United States (2)  ·  Austria (1)  ·  Belgium (1)  ·  Greece (1)  ·  Hungary (1)  ·  Ireland (1)  ·  Netherlands (1)

Results publications

PMID 27920566